Please assess the completion status of the following clinical trial:

Trial Title: Aminotransferase Trends During Prolonged Acetaminophen Dosing

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age 18 or older~Exclusion Criteria:~1. History of acetaminophen ingestion on any of the four days preceding study enrollment~2. Measurable serum acetaminophen level at time of enrollment~3. Viral markers of Hepatitis B or C, or viral markers of Hepatitis A with an ALT level greater than ULN during screening laboratory testing~4. Serum ALT or AST level greater than ULN at Screening or Day 0~5. Total bilirubin level greater than ULN at Screening or Day 0~6. INR level greater than ULN at Screening~7. Alkaline phosphatase level greater than ULN at Screening~8. Platelet count less than 125 10\^9/L at Screening~9. Known cholelithiasis~10. Positive pregnancy test at Screening (female participants only)~11. History of consuming more than an average of 3 alcohol containing drinks daily over the preceding 2 weeks~12. History of consuming 3 or more alcohol containing drinks on any given day during the 2 weeks prior to study enrollment~13. New prescription medication started within the previous 30 days~14. Currently taking isoniazid~15. Currently taking warfarin~16. Currently adheres to a fasting type diet as determined by self report~17. Currently has anorexia nervosa as determined by self report~18. Participant is clinically intoxicated, psychiatrically impaired or unable to give informed consent for any reason~19. Known hypersensitivity or allergy to acetaminophen

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- acetaminophen (Type: EXPERIMENTAL): acetaminophen, 4 grams/day (1 gram every 4 hours for 4 doses)
- placebo (Type: PLACEBO_COMPARATOR): placebo for acetaminophen 4 grams/day (2 caplets every 4 hours for 4 doses)

Based on this trial design, predict the completion outcome and termination type (if applicable).